Prostate And Other Male Cancers

TFs Operate Across Gene Loci Within Disease Phenotypes

April 16, 2018

"Our results nominate mechanisms that operate across risk loci within disease phenotypes, suggesting new models for disease origins," the authors write.

Group Exercise, Nutrition Aids Prostate Cancer Patients on ADT

April 10, 2018

At the 3-month follow-up, EX+D resulted in significantly greater improvements in mobility performance (P<0.02), muscular strength (P<0.01), body fat percentage (P<0.05), and fat mass (P<0.03), when controlling for baseline and androgen-deprivation therapy

Low-Dose Abiraterone Acetate Noninferior for Prostate Cancer

March 29, 2018

The researchers observed a greater effect on PSA in the LOW arm versus the STD arm (mean log-change, −1.59 versus −1.19); according to predefined criteria, the noninferiority of LOW was established.

Can Radiation Dose-Escalation Up Survival in Prostate CA?

March 16, 2018

The 8-year rates of OS were 76 and 75% with 79.2 and 70.2 Gy, respectively (hazard ratio, 1.00; 95% confidence interval, 0.83 to 1.20; P=0.98). The 8-year cumulative rates of distant metastases were 4 and 6% for the 79.2- and 70.2-Gy arms, respectively (hazard ratio, 0.65; 95% confidence interval, 0.42 to 1.01; P=0.05).

Erleada Approved for Non-Metastatic, Castration-Resistant Prostate Cancer

By February 15, 2018

Erleada is the first FDA-approved therapy to treat patients with non-metastatic castration-resistant prostate cancer.

Positive Results Released for Novel Prostate Cancer Tx

February 09, 2018

The researchers found that the median metastasis-free survival was 40.5 months in the apalutamide group and 16.2 months in the placebo group in the planned primary analysis performed after 378 events had occurred. Also significantly longer time to symptomatic progression was seen with apalutamide versus placebo.

Zytiga Approved for Metastatic High-Risk Castration-Sensitive Prostate Cancer

By February 08, 2018

The FDA approval was supported by results from the Phase 3 multinational, multicenter, randomized, double-blind, placebo-controlled LATITUDE trial (N=1,199) which evaluated Zytiga 1000mg once daily in combination with prednisone 5mg once daily vs placebo in newly diagnosed, metastatic high-risk CSPC patients who had not received prior cytotoxic chemotherapy.

Obesity and Prostate CA Recurrence: What's the Link?

January 26, 2018

The researchers found that there were more obese patients in the high- versus low-/intermediate-risk group (41.2 versus 32.0%; P=0.006).

Mediterranean Diet Linked to Reduced Risk of Aggressive Prostate Cancer

January 18, 2018

The researchers found that high adherence to a Mediterranean dietary pattern, rich in fruits and vegetables, fish, legumes, and olive oil, correlated with a lower risk of prostate cancer with a Gleason score greater than 6.

Personalized Genetic Test May Estimate Age of Prostate CA Diagnosis

January 12, 2018

"Polygenic hazard scores can be used for personalized genetic risk estimates that can predict for age at onset of aggressive PCa," the authors write.

Enzalutamide Seizure Risk Factor Assessed in mCRPC

December 08, 2017

Within 4 months of enzalutamide initiation, four patients (1.1%) had at least one confirmed seizure; three additional patients (0.8%) experienced a seizure within four months following the 4-month study period.

NDA Submitted for Novel Non-Metastatic CRPC Treatment

By October 11, 2017

Apalutamide, an investigational, next generation oral androgen receptor inhibitor, was assessed for safety and efficacy in the Phase 3 pivotal trial, ARN-509-003 (SPARTAN), which the NDA is based on.

Cancer Survival for Alternative vs. Usual Treatment Examined

August 18, 2017

Alternative medicine was independently associated with greater risk of death compared with conventional cancer treatment overall (hazard ratio [HR], 2.50), as well as in subgroups with breast (HR, 5.68), lung (HR, 2.17), and colorectal cancer (HR, 4.57).

Genetics Should Play a Bigger Role in Clinical Decision-Making

June 21, 2017

As home genetic testing grows, patients will be bringing their results to physicians for reaction and response. Physicians will need to be proactively prepared.

Efficacy of Abiraterone Examined in Newly Diagnosed Prostate CA

June 06, 2017

Researchers of 2 newly published studies found that abiraterone (Zytiga) lowers risk of death by nearly 40% when added to standard androgen deprivation therapy.

Existing Treatment Effective in Bile Duct CA Following Surgery

May 22, 2017

In the per-protocol analysis, the researchers found that the average survival after surgery for those receiving capecitabine was 53 months, compared to 36 months for those who only had surgery. Existing Treatment Should be Considered Standard of Care in Biliary Cancer

Study Examines ACA Impact on Early Cancer Detection

May 19, 2017

For breast cancer, the diagnosis of early disease increased from 47.8 to 48.9%. For colorectal cancer it rose from 22.8 to 23.7%. And for lung cancer from 16.6 to 17.7%.

New Zytiga Tablet Strength Available

By May 17, 2017

Zytiga was shown to lower serum testosterone and other androgens in patients enrolled in a Phase 3 placebo-controlled trial.

AUA 'Choosing Wisely' List IDs Unnecessary Tests, Treatments

By May 15, 2017

The 2017 AUA list contains evidence-based recommendations to guide conversations between physicians and patients about what care is appropriate.

Italian-Style Coffee Consumption May Reduce Prostate Cancer Risk

By April 26, 2017

Nearly 7,000 Italian men participating in the Moli-sani epidemiological study aged ≥50 years were monitored for an average of 4.25 years.

Prostate-Specific Antigen Testing Patterns Examined

April 25, 2017

In 2012 the USPSTF recommended against PSA testing for men of all ages.

Distinction Between Cancer Occurrence in U.S.-, African-Born Blacks

April 14, 2017

Research suggests differences in environmental, cultural, social, genetic factors

USPSTF Drafts Prostate CA Screening Recommendations

By April 11, 2017

The USPSTF performed a systematic review of the existing evidence and concluded that the potential benefits and harms of prostate-specific antigen (PSA)-based screening are "closely balanced" in men aged 55-69 years.

Overall Survival Examined for Adjunct Metformin Use in Prostate CA

April 11, 2017

The researchers found that survival curves showed that metformin use with docetaxel did not significantly improve prostate cancer-specific survival.

Environmental Toxins Linked to Multiple Diseases, Early Puberty

By April 07, 2017

These studies identified links to increased risks of thyroid, testicular and breast cancer, nonalcoholic fatty liver disease and even the early onset of puberty for boys, which can lead to diseases in adulthood.

Sleep Duration May Affect Prostate Cancer Mortality

April 04, 2017

Six hours of sleep a night was linked to a 29% higher risk of prostate cancer death compared to 7 hours. Men who were 65 or older showed no difference in the risk of death from prostate cancer.

Aspirin Use Linked to Reduced Risk of Cancer Death

April 04, 2017

The researchers found that regular aspirin use correlated with reduced risk of total mortality compared with nonregular use (multivariable-adjusted relative risks [RRs], 0.93 and 0.89 for women and men, respectively).

Androgen Deprivation Tx and Dementia: Is There a Link?

By March 30, 2017

Researchers analyzed the outcome of dementia among prostate cancer patients exposed to ADT vs. a lesser-exposed comparison group.

Pros and Cons of MRI versus Biopsy for Prostate CA Screening

March 28, 2017

The detection rate of high-grade prostate cancer was comparable for 6-TRUS-Bx, 12-TRUS-Bx, and MRI ± TBx; 10, 12, and 11%, respectively.

Are Antiemetic Prophylactics Being Overprescribed for Chemotherapy?

By March 24, 2017

Study authors identified a total of 8,545 patients undergoing 73,577 administrations of chemotherapy with minimal or low emetic risk.